Literature DB >> 31665414

Blast Exposure and Risk of Recurrent Occupational Overpressure Exposure Predict Deployment TBIs.

Jennifer N Belding1,2, Shannon Fitzmaurice1,2, Robyn Martin Englert1,2, Isabell Lee1,2,3, Brad Kowitz1,2, Robyn M Highfill-McRoy1,2, Cynthia J Thomsen1, Uade da Silva1.   

Abstract

INTRODUCTION: Traumatic brain injury (TBI) has been the leading cause of morbidity and mortality in recent military conflicts and deployment-related TBIs are most commonly caused by blast. However, knowledge of risk factors that increase susceptibility to TBI following an acute, high-level blast is limited. We hypothesized that recurrent occupational overpressure exposure (ROPE) may be one factor that increases susceptibility to mild TBI (mTBI) following blast.
MATERIALS AND METHODS: Using military occupational specialty as a proxy, we examined the effects of high versus low ROPE on mTBI following blast exposure. Initial analyses included 111,641 active-duty-enlisted U.S. Marines who completed the 2003 or 2008 version of the Post-Deployment Health Assessment. Final analyses examined probable mTBI screens among Marines with at least one qualifying exposure as a function of whether the exposure was a blast and level of ROPE (N = 12,929). This study was approved by the Institutional Review Board at the Naval Health Research Center.
RESULTS: Blast and ROPE were both independently and jointly associated with a probable mTBI. Marines who experienced a blast (vs other qualifying exposure) and those in high (vs low) risk occupations were 1.07 and 1.23 times more likely to sustain a probable mTBI, respectively. Furthermore, among those who experienced a blast during deployment, those in high-risk occupations were 1.45 times more likely than those in low-risk occupations to sustain a probable mTBI.
CONCLUSIONS: Blast exposure and ROPE were independently associated with mTBIs, and Marines with both blast exposure during deployment and ROPE were especially likely to sustain an mTBI. This suggests that ROPE heightens the risk of mTBI following blast. Ongoing research is examining the severity, symptomology, and sequelae of TBIs as a function of ROPE. © The Association of Military Surgeons of the United States. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2020        PMID: 31665414     DOI: 10.1093/milmed/usz289

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  4 in total

Review 1.  Getting on the Same Page: Consolidating Terminology to Facilitate Cross-Disciplinary Health-Related Blast Research.

Authors:  Jennifer N Belding; Michael Egnoto; Robyn M Englert; Shannon Fitzmaurice; Cynthia J Thomsen
Journal:  Front Neurol       Date:  2021-06-24       Impact factor: 4.003

2.  Neuronally-derived tau is increased in experienced breachers and is associated with neurobehavioral symptoms.

Authors:  Katie A Edwards; Kisha Greer; Jacqueline Leete; Chen Lai; Christina Devoto; Bao-Xi Qu; Angela M Yarnell; Elena Polejaeva; Kristine C Dell; Matthew L LoPresti; Peter Walker; Eric M Wassermann; Walter Carr; James R Stone; Stephen T Ahlers; Rany Vorn; Carina Martin; Jessica M Gill
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.379

3.  A Pilot Study of Whole-Blood Transcriptomic Analysis to Identify Genes Associated with Repetitive Low-Level Blast Exposure in Career Breachers.

Authors:  Rany Vorn; Katie A Edwards; James Hentig; Sijung Yun; Hyung-Suk Kim; Chen Lai; Christina Devoto; Angela M Yarnell; Elena Polejaeva; Kristine C Dell; Matthew L LoPresti; Peter Walker; Walter Carr; James R Stone; Stephen T Ahlers; Jessica M Gill
Journal:  Biomedicines       Date:  2022-03-17

4.  Occupational Risk of Low-Level Blast Exposure and TBI-Related Medical Diagnoses: A Population-Based Epidemiological Investigation (2005-2015).

Authors:  Jennifer N Belding; Robyn Englert; James Bonkowski; Cynthia J Thomsen
Journal:  Int J Environ Res Public Health       Date:  2021-12-08       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.